Dyne Therapeutics, INC Form 4 insider transactions

Douglas Kerr, Head of R&D and CMO of Dyne Therapeutics, Inc., reported multiple transactions in common stock on October 20, 2026.

Brian S Posner, a Director of Dyne Therapeutics, Inc., purchased 2,500 shares of common stock on October 2, 2026 for $16.00 per share.

Johanna Friedl-Naderer, Chief Commercial Officer of Dyne Therapeutics, Inc., sold 1,085 shares of common stock on September 4, 2026.

John Cox, CEO & President and a Director of Dyne Therapeutics, Inc., sold 5,658 shares of common stock on September 8, 2026 for $18.88 per share.

Jason P Rhodes, a Director of Dyne Therapeutics, Inc., sold 2,586,928 shares of common stock on August 13, 2026.

Johanna Friedl-Naderer, Chief Commercial Officer of Dyne Therapeutics, Inc., sold 226 shares of common stock on August 13, 2026 for $26.28 per share.

Douglas Kerr, Chief Medical Officer of Dyne Therapeutics, Inc., sold 1,556 shares of common stock on August 13, 2026 for $26.28 per share.

John Cox, CEO & President and a Director of Dyne Therapeutics, Inc., sold 4,986 shares of common stock on August 13, 2026 for $26.28 per share.

Erick Lucera, Chief Financial Officer of Dyne Therapeutics, Inc., sold 1,797 shares of common stock on August 13, 2026 for $26.28 per share.

Dyne Therapeutics Director Jason P. Rhodes reported the sale of common stock totaling over 600,000 shares across multiple transactions on July 6th and 7th, 2026, executed under a Rule 10b5-1 trading plan.

Dyne Therapeutics Director Jason P. Rhodes reported the sale of common stock valued at approximately $21.28 per share on June 26, 2026, and $21.14 per share on June 29, 2026, pursuant to a Rule 10b5-1 trading plan.

Dyne Therapeutics' Chief Financial Officer, Erick Lucera, sold 2,362 shares of common stock on June 25, 2026, to cover tax obligations related to vested restricted stock units.

Dyne Therapeutics Director Jason P. Rhodes reported the sale of common stock totaling over 100,000 shares across multiple transactions between June 23-25, 2026, executed under a Rule 10b5-1 trading plan.

Dyne Therapeutics Director Dirk Kersten reported transactions involving the sale of company stock, executed under a Rule 10b5-1 trading plan.

Dyne Therapeutics Chief Medical Officer Douglas Kerr sold company stock to cover tax obligations related to vested restricted stock units.

Dyne Therapeutics Chief Commercial Officer Johanna Friedl-Naderer sold shares to cover tax obligations related to vested restricted stock units.

Dyne Therapeutics CEO John Cox sold 2,683 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Director Edward Hurwitz was granted 35,152 stock options in Dyne Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director David Charles Lubner was granted 35,152 stock options in Dyne Therapeutics, Inc. on June 5, 2026.

Director Jason P. Rhodes was granted 35,152 stock options in Dyne Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Dirk Kersten was granted 35,152 stock options in Dyne Therapeutics, Inc. as part of a standard equity compensation.

Director Carlo Incerti was granted 35,152 stock options in Dyne Therapeutics, Inc. as part of standard equity compensation.

Director Catherine Stehman-Breen was granted 35,152 stock options in Dyne Therapeutics, Inc. as part of standard compensation.

Director Brian S. Posner acquired 2,000 shares of Dyne Therapeutics common stock and received a new stock option grant.

Director Brian S. Posner acquired 2,500 shares of Dyne Therapeutics, Inc. common stock at a price of $17.48 per share.

Dyne Therapeutics director Brian S. Posner purchased 2,500 shares of common stock at $17.12 per share.

Dyne Therapeutics Chief Commercial Officer Johanna Friedl-Naderer sold shares to cover tax obligations related to vesting restricted stock units.

Dyne Therapeutics Chief Medical Officer Douglas Kerr sold 1,564 shares of common stock for $18.36 per share to cover tax withholding obligations upon the vesting of restricted stock units.

Dyne Therapeutics CEO John Cox sold 3,311 shares of common stock to cover tax withholding obligations related to vesting restricted stock units, as disclosed in a Form 4 filing.

Director Jason P. Rhodes sold shares of Dyne Therapeutics, Inc. common stock via a pre-arranged Rule 10b5-1 trading plan.